AKT1 and hepatocellular carcinoma: In cancer therapy, oxymatrine inhibits iron death in hepatocellular carcinoma through the SIRT1/YY1/GPX4 axis [44], diosbulbin B targets YY1 to induce cell cycle arrest and apoptosis in non-small cell lung cancer [45], JAC1 inhibits the proliferation of triple-negative breast cancer by inhibiting YY1/HSF1/p-Akt signaling [46], the gold(III) porphyrin complex Gold-2a inhibits breast cancer WNT1 by enhancing YY1 promoter binding [47], and the nitric oxide donors DETANONOate and GIT-27NO reverse tumor resistance by interfering with NF-κB/Snail/YY1/RKIP or directly inhibiting YY1 [48,49].